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Synopsis The crystal structure of CYRI-B is revealed, providing a template to understand the role of 
this highly conserved eukaryotic protein in a variety of actin dependent cellular processes. 
Abstract In eukaryotes, numerous fundamental processes are controlled by the WAVE regulatory 
complex (WRC) that regulates cellular actin polymerization crucial to cell motility, cell-cell adhesion 
and epithelial differentiation. Actin assembly is triggered by interaction of the small GTPase Rac1 with 
CYFIP1, a key component of the WRC. Previously known as FAM49B, CYRI-B is a protein highly 
conserved across the Eukaryota which has recently been revealed to be a key regulator of Rac1 activity. 
Mutation, or alteration of CYRI-B expression, therefore, leads to altered actin nucleation dynamics with 
impacts on lamellipodia formation, cell migration and infection by intracellular pathogens. In addition, 
knockdown of CYRI-B expression in cancer cell lines results in accelerated cell proliferation and 
invasiveness. Here, the structure of Rhincodon typus (whale shark) CYRI-B is presented, the first to be 
reported of any CYRI family member. Solved by X-ray crystallography, the structure reveals that 
CYRI-B comprises three distinct α-helical subdomains and is highly structurally related to a conserved 
domain present in CYFIP proteins. The work presented here establishes a template towards a better 
understanding of CYRI-B biological function. 
1. Introduction 
Actin filament dynamics are central to a myriad of essential cellular processes such as cell migration, 
division and intracellular trafficking (Pollard & Cooper, 2009; Rottner et al., 2017; Rottner & Schaks, 
2019). Actin assembly is nucleated by cellular machines such as the ubiquitous Arp2/3 complex, which 
drives the generation of the branched actin networks underlying processes including lamellipodia 
formation and cell motility (Buracco et al., 2019). Arp2/3 activity is regulated by nucleation-promoting 
factors (NPFs), which thus provide spatial and temporal control of these processes (Campellone & 
Welch, 2010; Rotty et al., 2013). The best-characterised NPFs are those belonging to the Wiskott-





Aldrich syndrome protein (WASP) family, which stimulate Arp2/3 via C-terminal VCA (Verprolin-
homology, Central and Acidic regions) domains (Pollitt & Insall, 2009; Alekhina et al., 2017). The 
WASP family members WAVE1, WAVE2 and WAVE3 are central to cell motility and protrusion 
formation (Kurisu & Takenawa, 2009; Rottner & Schaks, 2019), and each functions as part of a 
heteropentameric complex termed the WAVE Regulatory Complex (WRC) (Chen et al., 2010, 2014). 
In the resting state, the WAVE VCA domain is hidden in the WRC structure (Ismail et al., 2009; Chen 
et al., 2010). Multiple signals have been reported that can trigger exposure of the WAVE VCA and 
consequent activation of Arp2/3, the best-characterised of these being interaction with the small GTPase 
Rac1 (Miki et al., 1998; Ismail et al., 2009; Chen et al., 2010), which is crucial for cell migration 
(Steffen et al., 2013). There are two possible sites of Rac1 interaction on the WRC. The original ‘A’ 
(‘adjacent’) site is located in the N-terminal part of CYFIP1 (Chen et al., 2010), a key component of 
the WRC, while the newly-identified ‘D’ (‘distant’) site is situated at the C-terminal extremity of the 
protein (Chen et al., 2017). While two Rac1 molecules can simultaneously bind to the WRC in vitro 
(Chen et al., 2017), only the ‘A’ site was found to be essential for its activation in vivo (Schaks et al., 
2018). Several studies reported that like CYFIP1, FAM49B interacts with the active form of Rac1 
(Shang et al., 2018; Fort et al., 2018), a well-conserved eukaryotic protein. FAM49B was consequently 
renamed CYRI-B for CYFIP-related Rac1 interactor (Fort et al., 2018). CYRI-B binding has been 
reported to block various Rac1-dependent signalling cascades in the cell, thereby controlling multiple 
critical cellular functions, including T cell activation (Shang et al., 2018), membrane protrusion, 
chemotaxis and cell migration (Fort et al., 2018; Whitelaw et al., 2019). By negatively regulating Rac1 
signalling, CYRI-B also reduces entry of several intracellular bacterial pathogens into both phagocytic 
and non-phagocytic host cells, and indeed is targeted for ubiquitin-mediated destruction by the action 
of an injected Salmonella virulence protein (Yuki et al., 2019). CYRI-B has also been suggested to play 
a role in certain cancers. Thus, expression of CYRI-B in pancreatic ductal adenocarcinoma cells is 
downregulated in the tumour microenvironment, leading to increased cell proliferation and invasion 
(Chattaragada et al., 2018). Furthermore, knockdown of CYRI-B expression increases cell proliferation 
in colorectal and liver cancer cell lines (Long et al., 2019), suggesting CYRI-B may act as a tumour 
suppressor. 
Here, we present the structure of Rhincodon typus (whale shark) CYRI-B, the first structure of any 
member of the CYRI protein family. Solved by X-ray crystallography at 2.4 Å resolution using the 
SAD method, the structure reveals three distinct, entirely α-helical, subdomains and a high structural 
similarity with a conserved domain of CYFIP1. Our work provides a basis to better understand the 
diverse and important roles of the CYRI protein family in eukaryotic cells. 
 





2. Materials and methods  
2.1. Cloning, expression and purification of CYRI-B (FAM49B) 
DNA fragments encoding CYRI-B (FAM49B) from Anthurium amnicola, Bison bison bison, 
Crocodylus porosus, Homo sapiens, Lingula anatine, Ornithorhynchus anatinus, Orussuss abientinus, 
Rhincodon typus, Tetranycus urticae and Tupaia chinensis were synthesised (IDT) and cloned into 
pET11a using Gibson assembly (Gibson et al., 2009). Fragments were designed to include an N-
terminal Solubility Enhancement Tag (SET2, Stratagene), a hexahistidine tag (his-tag) and a Tobacco 
Etch Virus (TEV) cleavage site upstream of the CYRI-B coding sequence. 
E. coli Rosetta (DE3) cells (Novagen) bearing the appropriate expression plasmid were grown at 37°C 
in 2YT media supplemented with 50 μg/mL of ampicillin and 20 μg/mL chloramphenicol. When the 
cells reached an OD600 of 0.8, the temperature was reduced to 18°C and protein expression was induced 
with 0.1 mM IPTG. After 16h at 18°C, bacteria were harvested by centrifugation at 6 000 g for 10 min 
at 4°C and the pellet resuspended in 40 mL of lysis buffer composed of 20 mM Tris pH 7.4, 150 mM 
NaCl, 0.25 mM Bond-Breaker TCEP solution (Thermo Scientific) and one tablet of EDTA-free 
protease inhibitor cocktail (Roche). Bacteria were lysed by cell disruption (Constant Systems) at 30 000 
psi and the lysate clarified by ultracentrifugation for 1h at 60 000 g and 4°C. The clarified lysate was 
then incubated with 2 mL of Ni-NTA agarose (Qiagen) for 1h at 4°C. The resin was then washed with 
20 mL of wash buffer (20 mM Tris pH 7.4, 500 mM NaCl, 0.25 mM TCEP) supplemented with 10 mM 
imidazole before elution with the same buffer containing only 150 mM NaCl and supplemented with 
250 mM imidazole. The eluate was dialyzed against 5 L of dialysis buffer (20 mM Tris pH 7.4, 150 
mM NaCl, 5 mM 2-mercaptoethanol). The N-terminal his-tag was removed using his-tagged Tobacco 
Etch Virus (TEV) protease produced from plasmid pTH24:TEVSH as described (Van Den Berg et al., 
2006). Cleavage reactions utilised 250 µM FAM49B and 185 µM TEV protease in a total volume of 10 
mL and were incubated for 4h at 22ºC. Free his-tags, uncleaved CYRI-B protein and TEV protease 
were removed by several passages over 2 mL of Nickel resin (Biorad Profinity). Recombinant CYRI-
B was concentrated to 10 mg/mL using a 10 kDa MWCO Amicon ultra centrifugal filter (Millipore), 
supplemented with 10% glycerol and stored at -80°C. 
For preparation of selenomethionine (SeMet) derivatized CYRI-B, the metabolic inhibition protocol 
was used (Van Duyne et al., 1993). E. coli Rosetta (DE3) cells carrying the CYRI-B expression plasmid 
were grown in M9 minimal medium supplemented with 50 μg/mL carbenicillin, 0.2% glucose, 2 mM 
MgSO4, 0.1 mM CaCl2 and 0.001% thiamine to an OD600 of 0.8. At this point the culture was 
supplemented with 60 mg/L selenomethionine, 50 mg/L leucine, isoleucine, valine and 100 mg/L 
lysine, phenylalanine and threonine. The temperature was reduced to 18ºC and cells were grown for a 





further 15 minutes before induction of protein expression with 0.1 mM IPTG. After a further 16h, cells 
were pelleted by centrifugation at 6 000 g for 6 min. The SeMet labelled CYRI-B was then purified and 
the his-tag removed by TEV proteolysis as described for the native protein.  
2.2. Analytical size-exclusion chromatography 
Size-exclusion chromatography (SEC) was utilised to confirm the oligomeric state of the native and 
SeMet-derivatized CYRI-B proteins. SEC was performed at room temperature using an ÄKTA Pure 
FPLC system (GE Healthcare) equipped with a Superdex 75, 10/300 GL column in 20 mM Tris pH 7.5, 
150 mM NaCl and 5 mM 2-mercaptoethanol. A total of 0.5 mg of native protein was applied on the 
column or 0.3 mg of the less soluble SeMet derivative, in a final volume of 100 μL. 
2.3. Native and SDS-PAGE gels 
The purity and oligomeric state of the recombinant CYRI-B proteins were analyzed using 7% native 
and 10% SDS-PAGE under non-reducing and reducing conditions respectively. Protein bands were 
visualised using Instant BlueTM (Expedeon). 
2.4. Crystallization  
Crystallization trials were set up in 2-drop MRC plates (Molecular Dimensions) using a Mosquito robot 
(TTP labtech). Crystals were grown using the sitting drop vapour diffusion method. Initial screening 
was performed using commercial crystallization screens (Structure Screen, MIDASplus, JCSG-plus 
(Molecular Dimensions) and Salt RX (Hampton Research)). Subsequent optimisation utilised 
homemade screens.  
Native CYRI-B protein at 10 mg/mL was mixed with the reservoir solution at a 1:2 ratio in a final 
volume of 1 μL over a reservoir of 80 μL. Crystals were obtained at 15°C in 0.2 M ammonium acetate, 
0.1 M MES pH 6.5 and 30% (w/v) glycerol ethoxylate, using seeds of crystals obtained in 0.1 M MES 
pH 6.5, 7-10% PEG8000 and 20% PEG1000. Single orthorhombic prisms approximately 300 x 40 x 15 
μm appeared the following day. Crystals were cryoprotected by the reservoir liquor and frozen in liquid 
nitrogen. 
The SeMet-substituted CYRI-B was less soluble than the native protein and was consequently only 
concentrated to 2.6 mg/mL in a buffer containing 20 mM Tris pH 7.5, 150 mM NaCl and 5 mM 
2-mercaptoethanol. Crystallization was carried out by mixing, at a 1:2 ratio, the protein with a 
precipitant solution composed of 0.2 M ammonium acetate, 0.1 M Bis-Tris, pH 5.5 and 25% PEG3350 
in a final volume of 1 μL. Crystals were obtained after one day with the same seed stock used for the 
native protein but were slightly smaller (approximate size 50 x 20 x 10 μm). They were cryoprotected 





with the reservoir solution supplemented with 10% (v/v) glycerol. Images of protein crystals together 
with a typical diffraction pattern are shown in Supplementary Figs. S1a and S1b. 
2.5. Data collection and structure determination 
The single-wavelength anomalous diffraction (SAD) data set was collected on beamline I03 at Diamond 
Light Source (DLS) from SeMet-labelled CYRI-B. A total of 720 images (0.04 s exposure, 0.5° 
oscillation) were collected on a Pilatus3 6M detector from a single crystal by illumination at 12 900 eV 
(0.9611 Å). The data were indexed and integrated with iMosflm (Battye et al., 2011) in P212121, scaled 
with Aimless (Evans & Murshudov, 2013) to a maximum resolution of 2.50 Å. The last 120 images 
were excluded due to radiation damage, as judged from batch I/σ(I) and Rmerge statistics. Anomalous 
scatterers were located with the HySS (Hybrid Substructure Search, Grosse-Kunstleve & Adams, 2003) 
module of Phenix (Adams et al., 2010; Liebschner et al., 2019). The 15 heavy-atom sites were input 
into Phaser (McCoy et al., 2007) for SAD phasing followed by density modification with Parrot 
(Cowtan, 2010) and model building with Buccaneer (Cowtan, 2006). The overall figure of merit for the 
final SAD phases was 0.48 rising to 0.57 after the first density modification. After each refinement step 
with Refmac (Murshudov et al., 2011), model inspection and building was performed with Coot 
(Emsley et al., 2010). The data were finally reprocessed at 2.40 Å and the model was refined with cycles 
of manual modification with Coot and refinement using Refmac first and Phenix for the last cycles 
including two TLS groups and automatic X-ray/stereochemistry weights. The final model has Rwork and 
Rfree factors of 0.2048 and 0.2415, respectively. 
The native dataset was collected on beamline I04 at Diamond. The 720 images (0.05 s exposure, 0.5° 
oscillation) were collected on a Pilatus 6M-F detector. The data were processed with iMosflm in P212121 
and scaled with Aimless, giving a data set composed of 13 266 unique reflections to a maximum of 2.37 
Å resolution. The structure was solved by molecular replacement with Phaser using the model obtained 
from the selenomethionine dataset. The model was then improved by several rounds manual building 
with Coot and refinement with Refmac first and Phenix for the last cycles using two TLS groups and 
automatic X-ray/stereochemistry constraints. The final model obtained has Rwork and Rfree factors of 
0.2251 and 0.2772, respectively. 
During refinement, eight ordered water molecules were manually added to the SeMet and native 
structures respectively. In both data sets, electron density was too weak to build residues 171 to 175. 
Both models were validated using tools from Coot, Rampage (Lovell et al., 2003) and Procheck 
(Laskowski et al., 1993). Data collection and structure refinement statistics are listed in Table 1. 
Coordinates and structure factors of the native and SeMet-derivatized proteins have been deposited in 
the Protein Data Bank (PDB) with the respective accession codes 6YJK and 6YJJ. 





Table 1 Data collection and refinement statistics  
Values for the outer shell are given in parentheses. 




   
Data Collection   
    Temperature (K) 100 100 
    Wavelength (Å) 0.9611 0.9795 
Crystal Parameters   
    Space Group P212121 P212121 
    a, b, c (Å) 40.4, 72.8, 107.3 39.8, 72.2, 107.8 
    α, β, γ (°) 90, 90, 90 90, 90, 90 
Reflection Data *   
    Resolution (Å) 72.82-2.40 (2.49-2.40) 60.01-2.37 (2.46-2.37) 
    Unique Reflections 13006 (1329) 13266 (1362) 
    Rsym 0.112 (0.965) 0.122 (0.962) 
    I/σ(I) 12.8 (2.1) 10.1 (2.0) 
    CC½  0.998 (0.782) 0.998 (0.590) 
    Completeness (%) 100.0 (100.0) 100.0 (100.0) 
    Multiplicity 





Refinement †   
    Resolution (Å) 53.66 (2.40) 60.01 (2.37) 
    Number of Reflections 12959 13207 
    Rwork / Rfree 0.2048 / 0.2415 0.2251 / 0.2772 
    Rms (Bond Lengths) (Å) 0.005 0.006 
    Rms (Bond Angles) (°) 0.70 0.84 
Model Composition   
    Protein atoms 2570 2573 
    Waters 8 8 
    Other 0 0 
Model B-factors   
    Protein atoms (Å2) 63.2 74.5 
    Waters (Å2) 42.5 45.5 
Ramachandran Statistics ‡   
    Favoured (%) 97.5 97.5 
    Allowed (%) 2.5 2.5  
    Outliers (%) 0.0 0.0 
   
 
 





* Reflection data is as reported by Aimless (Evans & Murshudov, 2013).  
† Refinement statistics as reported by Phenix (Adams et al., 2010; Liebschner et al., 2019).  
‡ Ramachandran statistics as reported by Rampage (Lovell et al., 2003). 
2.6. Electrostatic potential calculations and figure preparation 
Electrostatic potential profiles were calculated and visualized in PyMOL using the APBS Plugin (v2.1) 
(Baker et al., 2001; Jurrus et al., 2018) and PQR files generated by the PDB2PQR server (Dolinsky et 
al., 2004, 2007). Surface potential was set to ± 4.0 kT/e. All figures were generated with PyMOL v2.2.2. 
3. Results and discussion  
3.1. Structure of CYRI-B (FAM49B), an α-helical protein 
To facilitate structural studies, we cloned and expressed CYRI-B (FAM49B) from Homo sapiens and 
nine homologues. Most proteins either did not express well (O. anatinus and T. chinensis), were 
unstable after purification (A. amnicola, B. b. bison and O. abientinus) or failed, so far, to crystallize 
(L. anatine, C. porosus, T. urticae and H. sapiens). However, we successfully produced crystals of 
whale shark (Rhincodon typus) CYRI-B. After optimisation and screening of multiple crystals, we were 
able to obtain diffraction data at 2.37 Å resolution. We attempted to solve the structure by molecular 
replacement using the DUF1394 domain of CYFIP1 (PDB 3P8C) as it shares 21% sequence identity 
with whale shark CYRI-B and is predicted to be structurally similar (Yuki et al., 2019). However, these 
efforts were unsuccessful. 
We therefore produced a selenomethionine-substituted protein that allowed us to determine the structure 
of CYRI-B by SAD phasing. The native and SeMet protein crystals have similar unit cell dimensions 
and belong to the same orthorhombic space group, P212121. They were solved at resolutions of 2.37 and 
2.40 Å, respectively. Collection and refinement data are listed in Table 1 and representative electron 
densities for the native and SeMet-substituted structures are respectively shown in Supplementary 
Movie S1 and Movie S2. In both cases, a single molecule is present in the asymmetric unit. The two 
models are nearly identical and could be aligned with a Cα r.m.s.d. of 0.29 Å for 320 atoms. 
The structure of CYRI-B (FAM49B) is shown in Fig. 1. It reveals a protein comprised solely of α-
helices which can be divided into three linear subdomains. The N-terminal subdomain extends until 
residue 125 and consists of five α-helices, three of which form a 60 Å elongated α-helical hairpin 
extending the entire length of the protein. The Medial subdomain extends from residues 126 to 214 and 
exhibits a 90º-broken antiparallel helical hairpin, that covers one face of the N-terminal subdomain. The 
two antiparallel helices α6 and α9 split at the lowest part to surround the extended α4 helix of the N-





terminal subdomain. Finally, the C-terminal subdomain (215-324) consists of six α-helices which 
associate into a globular bundle located at the base of the structure. This bundle caps the lower half of 
the Medial subdomain and is elevated above helices α1 and α5 of the N-terminal subdomain. 
In both the native and SeMet structures, the flexible loop composed of residues 171 to 175 was too 
disordered to build and is therefore missing from the final models. This loop connects helices α7 and 
α8 of the Medial subdomain. A non-native serine, residual from the purification strategy, is present at 
the N-terminus of the structure. 
CYRI-B possesses five cysteines, one is located in the N-terminal region while the C-terminal 
subdomain has four. In the C-terminal region, the two cysteines 231 and 253 from helices α10 and α12 
are located too far apart (> 3 Å) to form an internal disulfide bond in our structure (Supplementary Fig. 
S2a). However, it is likely that in non-reducing conditions, these two helices are stabilised by a 
disulfide. Glycine 2 which is N-myristoylated in vivo (Fort et al., 2018) is located at the base of the 
structure (Fig. 1) and is freely accessible. 
 





Figure 1 Crystal structure of CYRI-B. Cartoon representation of the native CYRI-B from Rhincodon 
typus showing the N-terminal (green), Medial (yellow) and C-terminal (blue) subdomains. The 
myristoylation site of the protein (Fort et al., 2018) is indicated. Schematic linear organisation of the 
protein subdomains is represented underneath. 
 
Biochemical analyses of R. typus CYRI-B were conducted to confirm the oligomeric state of the protein 
found by X-ray crystallography. As presented in Fig. 2a, the native and SeMet derivative proteins 
migrate as a single band on both native and SDS-PAGE gels. Under denaturing conditions, proteins 
migrate with an apparent molecular weight of ~ 30 kDa, close to the CYRI-B theoretical size of 37 kDa. 
Further analysis of the purified proteins by size-exclusion chromatography (SEC) revealed a single peak 
which elutes close to 30 kDa on a calibrated gel filtration column (Fig. 2b). 
 
Figure 2 Oligomeric state of CYRI-B. (a) Native PAGE, left, and SDS-PAGE, right, gels of CYRI-B 
native (Nat.) and selenomethionine (Se) derivative proteins. Molecular masses of protein standards (M) 
are shown. (b) Size-exclusion chromatography profiles of indicated proteins. 






Gel electrophoresis and SEC results corroborate the crystallographic data, confirming the monomeric 
state of CYRI-B in solution. 
3.2. Comparison with human CYRI-B and relatives 
3.2.1. Whale shark and human CYRI-B are almost indistinguishable 
CYRI proteins are ubiquitous and highly conserved as illustrated by the alignment of sequences from 
multiple species (Supplementary Fig. S3a). For example, whale shark and human CYRI-B share a 
sequence identity of 93% (Supplementary Fig. S3b). Thus, over the 324 residues of both proteins, 12 
substitutions are conservative, 5 semi-conservative and only 7 lead to a modification of the amino acid 
physico-chemical properties (Fig. 3a). Most of these substitutions localise to residues 10-18 which are 
located in a loop connecting helices α1 and α2 within the N-terminal subdomain (Fig. 3b). This region 
is poorly conserved in CYRI-B proteins (Supplementary Fig. S3a) and outside the presumed 
Rac1-binding region (Fort et al., 2018). A few other mutations are located at the apex of this subdomain. 
The Medial and C-terminal subdomains are almost entirely conserved between the two species as they 
only contain two and three conservative substitutions respectively. As a result, the surface charge 
distribution of whale shark CYRI-B and the human homology model are near identical (Fig. 3c and 
Supplementary Movie S3). 
 
Figure 3 Comparison of human and whale shark CYRI-B reveals high sequence similarity. (a) 
Alignment of whale shark and human protein sequences where divergent amino acids are represented 
in red, and identical residues are symbolised by a dot. Secondary structure of whale shark CYRI-B is 
shown above the sequence, using the same colour code as in Fig. 1. Alignment was generated with the 
NCBI Blast program (Altschul et al., 1997, 2005). (b) Side chains of dissimilar residues between the 
whale shark and human proteins are represented as spheres on each subdomain of the whale shark 





CYRI-B structure. Non-conservative differences between the two proteins are shown in bold in (a) and 
(b). (c) Views of the electrostatic surface of whale shark, left, and human (Phyre homology model), 
right, CYRI-B proteins. A 360º rotation tour is presented in Supplementary Movie S3. 
3.2.2. Comparison of CYRI-A and CYRI-B isoforms 
Two isoforms of CYRI proteins exist in many species: CYRI-A and CYRI-B. Some cells express only 
CYRI-B, such as Jurkat T cells and others both (mouse T cells) (Shang et al., 2018). The two proteins 
have a sequence identity of approximately 80% across multiple species including whale shark and 
human (Supplementary Fig. S3b), yet are functionally distinct. While a multitude of roles have been 
ascribed to CYRI-B, a clear function for CYRI-A has not been defined. 
We compared the two isoforms of the whale shark proteins and mapped the thirteen substitutions which 
lead to modification of the amino acid physico-chemical properties on our CYRI-B structure (Fig. 4a). 
Most of them are located in the N-terminal subdomain, some on the flexible loop located between 
helices α1 and α2 and several along the extended α4 helix. Some of these substitutions modify the 
surface electrostatic potential (Fig. 4b). Thus CYRI-A is predicted to have a negatively-charged patch 
at the bottom of the structure where Gly109 in the -B isoform is replaced by a glutamate in the -A 
protein. Conversely, the presence of a glutamate (Glu73), absent in CYRI-A, leads to the formation of 
a negative patch at the apex of CYRI-B. Sequence analysis reveals these differences are conserved in 
CYRI proteins from other species (Fig. 4c) but until more is known about the function of CYRI-A, the 
significance of these differences remains unclear. 
 
Figure 4 Comparison between whale shark CYRI-A and -B. (a) Radical substitutions between CYRI-
A and -B as indicated by Clustal Omega (Sievers et al., 2011) are shown as blue spheres on the CYRI-
B structure. The corresponding residues in CYRI-B are indicated. (b) Electrostatic surface of CYRI-A 





(Phyre homology model) and CYRI-B (crystal structure). (c) Sequence alignment of multiple CYRI-A 
and CYRI-B proteins highlighting residues 73 and 109 (R. typus CYRI-B numbering). Abbreviations 
are as follows: If, I. furcatus; Rt, R. typus; Xl, X. laevis; Ch, C. horridus; Hs, H. sapiens; Fc, F. catus 
and Ms, M. musculus. The full sequence alignment in provided in Supplementary Fig. S3a. 
 
3.3. Similarity with CYFIP1 from the WAVE regulatory complex (WRC) 
The ubiquitous CYFIP protein is a component of the WAVE regulatory complex (WRC). Two CYFIP 
isoforms exist, 1 and 2, which both contain a DUF1394 domain (residues 59-301, human numbering) 
also shared by CYRI proteins. Despite a relatively low sequence identity of 21% between human 
CYRI-B and the human CYFIP1 DUF1394 domain, the two regions are predicted to be structurally 
homologous (Yuki et al., 2019). The comparison of CYFIP1 DUF1394 domain (PDB 3P8C) with our 
structure of CYRI-B confirms this prediction (Fig. 5a). The two proteins are strikingly similar and can 
be superposed with a r.m.s.d. score of 3.4 Å over 240 Cα and between 1.8 and 2.4 Å for the individual 
N-terminal, Medial and C-terminal subdomains (Fig. 5b). 
Interestingly, the disordered loop (residues 169-181) connecting α7 and α8 is six residues longer than 
the corresponding region of CYFIP1 (residues 195-201). This loop constitutes one of the less conserved 
regions in CYRI-A and -B proteins (Supplementary Fig. S3a). Residues 171-175 which are missing in 
our structure could not be built based on the CYFIP1 structure as the flanking regions of the loop fold 
slightly differently in the two proteins (Supplementary Figs. S4a and S4b). Thus, helix α7 of CYRI-B 
is one turn longer than the corresponding helix in CYFIP1. The supplementary turn allows the 
interaction between Asn74 and the side chain of Gln318 belonging to a symmetry mate. Similarly, helix 
α8 of CYRI-B terminates one turn earlier, the loop unfolding towards the back of the structure where 
Asn177 interacts with the main chain of Asp290 belonging to a different symmetry mate. Moreover, 
the position of the loop in CYFIP1 is not compatible with the packing of CYRI-B crystal 
(Supplementary Fig. S4c). Indeed, the α4 apex of a symmetry mate would clash with an extra α-turn of 
α8 whereas the packing of the WRC crystal (PDB 3P8C) allows both conformations of this linker 
region. 
 
We examined the conservation of spatially proximal cysteines 231 and 253 (see section 3.1), in CYRI 
proteins and CYFIP homologues. These cysteines are conserved in both CYRI-A and -B isoforms but 
in CYFIP homologues, only the equivalent of Cys231 is conserved (Supplementary Fig. S2b). 
Examination of CYFIP protein sequences and CYFIP1 structure (PDB 3P8C, Chen et al., 2010) does 





not reveal a plausible partner for Cys231. The significance of these conserved cysteines for the 
biological function of CYRI and CYFIP remains to be clarified. 
 
The comparison of the two protein structures also highlights differences in the C-terminal subdomain. 
In CYRI-B, a loop connects α13 and α14 whereas in the equivalent region of CYFIP1, an 11 residue β-
hairpin is present (Fig. 5a). This hairpin mediates both intra- and interdomain interactions in CYFIP1 
(Fig. 5c, bottom left). Thus, the side chain of Asp310, located at the apex of the hairpin, forms a 
hydrogen bond with the Tyr84 hydroxyl of the N-terminal subdomain and main chain amides of Phe626 
and Phe627 from the FragX-IP domain (residues 389-1222 of CYFIP1). Interaction with the FragX-IP 
domain is further stabilised by a hydrogen bond between Gln312 and the side chain of Ser413. 
 
Figure 5 CYRI-B and CYFIP1 present a high degree of structural similarity. (a) Side-by-side view of 
the CYRI-B (left) and CYFIP1 DUF1394 domain (PDB 3P8C, right) structures. Colour code of CYRI-
B is as Fig. 1. The presence of an extra hairpin in CYFIP1 is indicated. (b) Secondary structure 
alignment of the N-terminal (green), Medial (yellow) and C-terminal (blue) subdomains of the two 
proteins. The r.m.s.d. score and Cα number are shown beside each alignment (from Superpose, Krissinel 





& Henrick, 2004). (c) Top, overall structure of the WAVE regulatory complex, WRC (PDB 3P8C). The 
DUF1394 domain of CYFIP1 is coloured as in (a). Bottom left, close-up view of the 304-314 hairpin 
of CYFIP1 showing residues involved in hydrogen interactions with the rest of the protein (grey). 
Bottom right, superposition of CYRI-B on the DUF1394 domain of CYFIP1 showing the absence of 
the 304-314 hairpin. An asterisk indicates a steric clash. 
 
CYFIP1 has been shown to bind Rac1 (Chen et al., 2010) and mutations that impair binding form a 
patch on CYFIP1 (Fig. 6a). Two of these mutations, C179R and R190D, are positioned on the DUF1394 
domain of CYFIP1. Similarly, Shang and co-authors depicted the interaction of CYRI-B with Rac1 
using co-immunoprecipitation and GST pull-down assays (Shang et al., 2018). The association was 
reinforced with active forms of Rac1, i.e. the nucleotide-bound form and the constitutively activated 
G12V mutant. They subsequently identified a series of mutations which abolished the function of 
CYRI-B in vivo. 
We mapped these mutations on our structure of CYRI-B (Figs. 6a and 6b). None of the residues are 
involved in intra-protein interactions, which is also the case for the two CYFIP1 mutants described to 
diminish the interaction between a modified version of the WRC and Rac1 (Fig. 6b) (Chen et al., 2010). 
 
Figure 6 Predicted association of Rac1 with CYRI-B and CYFIP1. (a) Site directed mutagenesis data 
mapped onto the R. typus CYRI-B crystal structure. Mutations in CYRI-B (black label) that impair (red 
spheres) or do not affect (blue spheres) its function in vivo (Shang et al., 2018) are shown. Green labels 
indicate mutations in the CYFIP1 DUF13243 domain that perturb the association of the WRC complex 
with Rac1 (Chen et al., 2010). (b) Close-up views of the predicted Rac1-interacting regions of CYRI-
B (left) and CYFIP1 (right), coloured as in Fig. 5. Residues leading to effective mutations in (a) are 
represented as cyan sticks with the corresponding mutated residue indicated. Electron densities of 
CYRI-B side chains are shown as blue mesh contoured at a sigma level of 1. 
 
In both CYRI-B and CYFIP1, helix α7, which comprises the majority of the residues predicted to 
constitute the Rac1-binding region, is stabilised by interactions with the antiparallel helix α8 and 





through a conserved aspartate that interacts with the loop joining helices α2 and α3 of the N-terminal 
subdomain (Fig. 6b, left). Thus, in CYRI-B, Asp155 forms hydrogen bonds with the hydroxyl of Tyr56 
and the backbone amide of Ala59 while the equivalent CYFIP1 residue, Asp184, forms a H-bonding 
network with Trp86, Cys89 and Ser90 (Fig. 6b, right).  
The highly conserved Arg161 of CYRI-B adopts an identical orientation to the equivalent residue in 
CYFIP1 (Arg190). This arginine is believed to play a central role in the association with Rac1 (Chen et 
al., 2010; Fort et al., 2018; Shang et al., 2018). The side chain of a second conserved arginine (Arg160) 
in CYRI proteins forms extensive H-bonds with the side chain carbonyl groups of Asn181 and Asn185 
and with the hydroxyl of Ser188, whereas the equivalent residue in CYFIP1 (Lys189) interacts with 
Ser207 carbonyl and hydroxyl groups. Interestingly, mutation of the conserved Arg160 to aspartate 
abolishes the interaction of CYRI-B with the activated Q61L Rac1 variant (Fort et al., 2018). It is 
possible that this is due to a local disruption of the secondary structure as Arg160 stabilises the 
interaction of α7 and α8. Alternatively, the presence of two consecutive positively charged amino acids 
may be crucial for the recruitment of Rac1 in which case Arg160 may alter conformation to interact 
with specific residues of Rac1. 
4. Conclusion 
In summary, we have revealed the structure of CYRI-B, also called FAM49B, the only described 
negative regulator of cellular actin assembly mediated by the WAVE regulatory complex (WRC) (Fort 
et al., 2018; Whitelaw et al., 2019). Our structure, the first reported of any member of the CYRI family, 
reveals a protein entirely composed of α-helices and organised into three distinct subdomains. CYRI-B 
exhibits significant structural homology with CYFIP1, a component of the WRC that interacts with the 
small GTPase Rac1, to promote actin polymerisation (Bompard & Caron, 2004; Pollitt & Insall, 2009). 
The similarity in structures suggest CYRI-B interacts with Rac1 in the same manner as CYFIP1 and 
therefore regulates actin dependent processes by competition with the WRC for Rac1 binding. Residues 
previously described as vital for CYRI-B function (Shang et al., 2018) cluster on a conserved helix 
which is likely to be central to Rac1 interaction. This study provides the structural basis to understand 
the function of CYRI proteins in a variety of fundamental cellular processes. 
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Supporting information  
 
 
Figure S1 Crystallization and diffraction of R. typus CYRI-B (FAM49B). (a) Single orthorhombic 
prism-shaped crystals of native (left) and selenomethionine (SeMet, right) CYRI-B. (b) A typical 










Figure S2 Location of cysteines in CYRI-B, showing a potential C231-C253 disulfide bond. (a, left) 
The five cysteines of CYRI-B are shown as red sticks on a cartoon representation of the R. typus crystal 
structure. (a, right) Close-up view showing electron density for the Cys231 and Cys253 side chains on 
the native (top) and selenomethionine (SeMet) derivative (bottom) proteins, crystallized in the presence 
of 2-mercaptoethanol. The mesh represents a weighted 2|Fo|-|Fc| electron density map contoured at 1 
σ. The beta carbons of the two cysteines are 3.7 and 4.1 Å apart in the selenomethionine and native 
structure, respectively, compatible with the formation of a disulfide bond in non-reducing conditions. 
(b) Multiple sequence alignment of region 227 to 258 (R. typus CYRI-B numbering) of CYRI-A, CYRI-
B, and 241 to 269 of CYFIP1 and CYFIP2 proteins. Alignment was performed with Clustal Omega 
(Sievers et al., 2011) and the following sequences: R. typus, Rhincodon typus (NCBI XP_020388351.1 
and XP_020368600.1); D. rerio, Danio rerio (Q5TZ57, Q6TLE5, Q90YM8 and A5A5E1); M. 
musculus, Mus musculus (Q8BHZ0, Q921M7, Q7TMB8 and Q5SQX6); B. taurus, Bos taurus 
(Q17QT7, Q2KJI3, E1BN47 and F1MX60); H. sapiens, Homo sapiens (Q9H0Q0, Q9NUQ9, Q7L576 
and Q96F07); D. leucas, Delphinapterus leucas (A0A2Y9PLS0 and A0A2Y9PRF5). Except otherwise 
specified, sequences for CYRI-A, CYRI-B, CYFIP1 and CYFIP2 proteins respectively are from 
Uniprot. Annotation of R. typus genome did not allow clear identification of CYFIP proteins, which 
were substituted by CYFIP1 and CYFIP2 sequences of the related, Beluga whale (D. leucas). Residues 
are coloured according to the conservation symbols given by Clustal Omega. 
 
  













Figure S3 Sequence alignment of CYRI (FAM49) proteins across different species. (a) Alignment 
was generated with Clustal Omega (Sievers et al., 2011) using the following protein sequences: I. 
furcatus, Ictalurus furcatus (Uniprot E3TCC8 and E3TCX7); R. typus, Rhincodon typus (NCBI 
XP_020388351.1 and XP_020368600.1); G. gallus, Gallus gallus (Uniprot Q5ZI04 and 
A0A3Q2TTC4); X. laevis, Xenopus laevis (Uniprot Q0IHF5 and Q8AVE9); C. horridus, Crotalus 
horridus (Uniprot A0A0K8RVD5 and A0A0B8RNP7); H. sapiens, Homo sapiens (Uniprot Q9H0Q0 
and Q9NUQ9); F. catus, Felis catus (Uniprot A0A5F5XX33 and M3WMY8); M. musculus, Mus 
musculus (Uniprot Q8BHZ0 and Q921M7). Conservation at each (0, least conserved; 9 most conserved) 
was assessed in Jalview 1.0 and displayed beneath the sequence alignment. (b) Identity matrix based on 
the aligned sequences, generated by Clustal Omega. 
 






Figure S4 Close-up view of the disordered loop in R. typus CYRI-B. The loop that connects helices 
α7 and α8 is shown in purple in our crystal structure of CYRI-B (a) or in CYFIP1 (b, PDB 3P8C). It is 
composed of residues 169 to 181 in CYRI-B (195-201 in CYFIP1) and residues 171-175 were too 
disordered to model. Main local interactions between residues of the Medial subdomain and residues 
belonging to symmetry mate proteins are represented in CYRI-B structure. (c) Close-up view of 
CYFIP1 aligned on CYRI-B structure showing steric clash with one of the CYRI-B symmetry mates 
(black). A dotted red square highlights the position of the steric hindrance. 
 
Movie S1 Representative electron density of the native CYRI-B (FAM49B) structure. A weighted 
2|Fo|-|Fc| electron density map, calculated with model phases, is shown as grey mesh contoured at 1 σ. 
 
Movie S2 Camera tour of the selenomethionine (SeMet) derivatized CYRI-B (FAM49B) structure. The 
first half of the movie shows the anomalous difference Fourier map surrounding selenium atoms as a 
blue mesh contoured at 3 σ. The second half of the film shows a weighted 2|Fo|-|Fc| electron density 
map, calculated with model phases, as grey mesh contoured at 1 σ. 
 
Movie S3 Electrostatic surface of whale shark and human CYRI-B. Full 360º rotation movie around 
the y-axis showing the electrostatic surface of the whale shark CYRI-B crystal structure, left, and human 
homology model, right. 
